May I suggest to all holders, continue to email directly seeking...

May I suggest to all holders, continue to email directly seeking clarification on progress re. various projects underway. Whilst you may not receive direct answers given market sensitivities it will send a message that holders are paying attention and that the company needs to disclose any "information that a reasonable person would expect to have a material effect" on the share price. (ASX Listing rule 3.1)

Sitting on "material" information is not acceptable and I for one have had enough. Vague throwaway lines hidden in a half yearly will not suffice, timely updates are required. Any material information being sat on by the company re. developments in areas such as listed below would see heavy fines and/or delisting.

My areas of interest re. updates/disclosure are:

1. NMRC; Campylobacter/ETEC:
.Q1/Q2 2021 Active drug substance manufacturing due for completion.
.Q2 2021 NMRC to file for IND with FDA for new drug substance.
.Q3/Q4 2021 NMRC to start two clinical trials.
.Preliminary read-outs by end of 2021.

2. Monash/ SARS-CoV-2:
.Positive update received re. inhibiting properties. However no timeframes were provided re. next phase.
.What discussions surrounding collaborations with Gov/Big Pharma are being held.
.The progress being made in isolating the compound/s responsible for the inhibiting effects.

3. IMM-124E:
.IND submission to FDA re phase III trial.
.Trial that was to start at the end of April 2021. NCT04605783

4. IMM529:
.FDA filling for ODD status. Very vague statements made in last half yearly.
.IND submission to FDA surrounding trial development re. CDI.

My thoughts only.